SynthesisFrontiers in immunology2025
Effectiveness of "tumor necrosis factor inhibitors" in monogenic hereditary recurrent fevers in children and adolescents: a systematic review.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This systematic review aims to evaluate the clinical effectiveness of tumor necrosis factor (TNF) inhibitors in treating monogenic hereditary recurrent fevers (HRFs) in children and adolescents. Methods: We conducted a comprehensive literature search across MEDLINE, EMBASE, and Scopus up to May 2024, including case reports, case series, and observational studies involving pediatric patients with HRFs treated with TNF inhibitors. Articles were screened and selected based on PRISMA guidelines. Results: Eleven pediatric cases were identified from ten studies, including patients with FMF (n=2), MKD/MKD (n=5), TRAPS (n=2), and CAPS (n=2). Etanercept was the most frequently used TNF inhibitor (10/11 cases), and infliximab was used in one FMF case. Follow-up duration ranged from 3 months to 4 years. Clinical responses varied: full remission in TRAPS cases; partial improvement in some MKD and CAPS cases; and no significant effect in several FMF and MKD/MKD patients. Etanercept showed the best outcomes in TRAPS, while responses in CAPS and MKD/MKD were inconsistent. Clinical trial registration: TNFi may offer a therapeutic option for selected pediatric HRF cases, particularly colchicine-resistant FMF with articular symptoms or where IL-1 blockers are unavailable. However, their efficacy appears limited and variable across HRF subtypes. Larger studies are needed to better define the role of TNF inhibitors in pediatric HRFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.